

# **Novartis iptacopan meets primary endpoints in Phase II study in rare kidney disease C3 glomerulopathy (C3G)**

Nov 04, 2021

---

**Source URL:** <https://www.novartis.com/us-en/news/media-releases/novartis-iptacopan-meets-primary-endpoints-phase-ii-study-rare-kidney-disease-c3-glomerulopathy-c3g-0>

## **List of links present in page**

- <https://www.novartis.com/us-en/us-en/news/media-releases/novartis-iptacopan-meets-primary-endpoints-phase-ii-study-rare-kidney-disease-c3-glomerulopathy-c3g-0>